The global isothermal nucleic acid amplification technology market size is projected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising prevalence of infectious diseases.
In the field of molecular biology and recombinant DNA technologies, the isothermal nucleic acid amplification technology (INAAT) is primarily used to identify and analyze nucleic acids. This technique is often used to diagnose infectious, genetic, and inherited disorders quickly, accurately, and precisely using DNA, RNA, cells, proteins, small molecules, and ions. The amplicons created by this technique are used to make a variety of nucleic acid nanomaterials that are employed in biomedicine, bioimaging, and biosensing. They are also used to test for HIV, Tuberculosis, influenza, hepatitis A and B, chlamydia, and gonorrhea (CT/NG), among other infectious disorders.
Wide the rising demand for advanced diagnostic technology, the development of recombinase polymerase amplification (RPA), single primer isothermal amplification (SPIA), and strand displacement amplification (SDA) are key aspects for the market expansion.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing number of cancer and other chronic conditions along with growing demand for effective diagnostic and treatment options are expected to drive the market growth during the forecast period.
- Wide applications of loop-mediated isothermal amplification (LAMP) tests for DNA and RNA amplification as well as the detection of genetically modified organisms (GMOs) are expected to boost the market growth.
- Rising number of aging population worldwide and the increase in the adoption of INAAT over other molecular diagnostic techniques are major factors driving the market growth during the forecast period.
- Stringent rules imposed by organizations such as World Health Organization (WHO) as well as wide reluctance to replace conventional PCR solutions with newer ones among patients in low-income nations are projected to hamper the market growth.
- Lack of awareness and relatively high cost of the advanced diagnostics present as key challenges that can restrict the market expansion during the forecast period.
- Ongoing R&D in the field of microbiology and rapid technological advancements to develop high-ended diagnostic devices are projected to offer lucrative opportunities for the market players.
Scope of the Report
The report on the global isothermal nucleic acid amplification technology market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Isothermal Nucleic Acid Amplification Technology Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Products (Instrument and Reagent), Technology (NASBA, HAD, LAMP, SDA, SPIA, NEAR, TMA, RCA, RPA, SMAP2, and Others), Applications (Blood Screening, Infectious Disease Diagnostics, Cancer, and Others), and End-users (Hospitals, Central & Reference Labs, and Others)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Alere, Inc.; bioMerieux SA; Eiken Chemical Co. Ltd.; Hologic, Inc. (Gen-Probe); Lucigen; QIAGEN; Quidel Corporation; Thermo Fisher Scientific; and Becton, Dickinson & Company
Market Segment Insights
Reagent segment is expected to hold a key share of the market
Based on products, the isothermal nucleic acid amplification technology market is bifurcated into instrument and reagent. The reagent segment is expected to hold a key share of the market during the forecast period owing to considerable usage of the products in hospitals and primary healthcare settings. Consumables and reagents are widely utilized as compared to instruments, which is extensively propelled by growing R&D programs and activities from key players. However, the instruments segment is anticipated to expand at a rapid pace during the forecast period due to the introduction of devices that are improved in terms of precision, speed, and portability.
TMA segment to account for a key market share
On the basis of technology, the market is segmented into SDA, SPIA, NEAR, RCA, RPA, SMAP2, nucleic acid sequence-based amplification (NASBA), helicase-dependent amplification (HDA), loop-mediated isothermal amplification (LAMP), transcription-mediated amplification (TMA), and Others. The TMA segment is expected to account for a key share of the market during the forecast period as it is one of the most commercial successful technology widely employed by the players and was the first INAAT introduced in the market. On the other hand, the LAMP and HDA segment is anticipated to expand at a rapid pace during the forecast period.
Infectious disease diagnostics segment is expected to hold a major market share
In terms of applications, the isothermal nucleic acid amplification technology market is segmented into blood screening, infectious disease diagnostics, cancer, and others. The Infectious disease diagnostics segment is expected to hold a major share of the market during the forecast period owing to the introduction of more particular kits and the rising prevalence of disorders such as HIV, hepatitis A and B, and STDs such as chlamydia and gonorrhea. In addition, the growing demand for quick testing to diagnose infectious diseases and prevent the diseases spread particularly in low-income countries is likely to drive growth.
On the other hand, the blood screening segment is anticipated to expand at a rapid pace during the forecast period owing to increased number of blood transfusions across the world. INAAT is extensively used to screen transfused blood for infectious organisms in order to prevent epidemics and limit their spread.
Hospitals segment is expected to register a high CAGR
Based on end-users, the market is divided into hospitals, central & reference labs, and others. The hospitals segment is expected to register a high CAGR during the forecast period due to wide adoption of wireless communication and miniaturized point-of-care devices are being developed, offering single-level access to diagnostic results across the hospital. Automation of a large quantity of samples for infectious disease diagnosis and a requirement for accurate results offered by hospitals are all expected to boost the segment growth.
On the other hand, the central & reference labs segment is anticipated to expand at a rapid pace during the forecast period due to an increasing number of reference laboratories and high adoption of novel & accurate molecular diagnostic techniques.
North America segment is anticipated to dominate the market
On the basis of regions, the isothermal nucleic acid amplification technology market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market with an impressive CAGR during the forecast period. The regional market growth can be attributed to established research infrastructure and rising research initiatives in economies such as the US and Canada. Moreover, increasing demand and investments from foreign players to develop advanced technology for diagnostics products by expanding the scope for the existing research activities in the region play key roles in the regional market expansion.
On the other hand, the market in Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to increase in disposable income, increased investments in healthcare facilities, and unfulfilled clinical demands.
Segments Covered in the Report
The global isothermal nucleic acid amplification technology market has been segmented on the basis of
- Blood Screening
- Infectious Disease Diagnostics
- Central & Reference Labs
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
- Alere, Inc.
- BioMerieux SA
- Eiken Chemical Co. Ltd.
- Hologic, Inc. (Gen-Probe)
- Quidel Corporation
- Thermo Fisher Scientific
- Becton, Dickinson & Company
Key players competing in the isothermal nucleic acid amplification technology market are Alere, Inc.; bioMerieux SA; Eiken Chemical Co. Ltd.; Hologic, Inc. (Gen-Probe); Lucigen; QIAGEN; Quidel Corporation; Thermo Fisher Scientific; and Becton, Dickinson & Company.
Several of these key players are actively engaged in the adoption of various business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and Customized products and applications, which are likely to enhance their market shares.